SG
NTLA icon

Societe Generale’s Intellia Therapeutics NTLA Stock Holding History

Societe Generale’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$374K Buy
+17,509
New +$466K ﹤0.01% 1848

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Societe Generale's NTLA Position: Q2 2016 in Review

Societe Generale opened a new position in Intellia Therapeutics (NTLA) in Q2 2016: 17,509 shares worth $374K. The stake represents ﹤0.01% of the portfolio and ranks #1848 among its holdings.

62 funds tracked by Wall St. Rank hold NTLA as of Q2 2016.

  • Societe Generale held 17,509 shares of Intellia Therapeutics worth $374K as of Q2 2016.
  • Intellia Therapeutics was a new Societe Generale position in Q2 2016.
  • Intellia Therapeutics made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #1848 holding.
  • 62 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.